The purpose of this study is to find a dose of Nivolumab that can be safely added to Dasatinib in patients with Chronic Myeloid Leukemia.
Name: Dasatinib
Type: DrugArm 1: Dasatinib + Nivolumab
Name: Nivolumab
Type: DrugArm 1: Dasatinib + Nivolumab
Description: Measured by the Dose limiting Toxicities determined based on the incidence and intensity of selected drug related adverse events, Incidences of Adverse events, Incidences of Serious adverse events, and Frequencies of abnormal Laboratory tests (summarized by worst toxicity grade)
Measure: Safety and Tolerability for the combination of Dasatinib and Nivolumab Time: Up to 2 years (approximately)Description: Based on MMR is defined as >= 3-log reduction in BCR-ABL transcripts or a ratio of <= 0.1% on the International Scale (IS) MR is defined as 4.5-log reduction in BCR-ABL transcripts or a ratio of 0.00316% on the IS
Measure: Major Molecular Response (MMR) and Molecular Response (MR) rates Time: 6, 12, 24, and 36 monthSingle Group Assignment
There are 2 SNPs
T315I or T315A) For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. --- T315I --- --- T315A ---
T315I or T315A) Chronic Myeloid Leukemia Leukemia Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive null --- T315I --- --- T315A ---
T315I or T315A) For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. --- T315I ---
T315I or T315A) Chronic Myeloid Leukemia Leukemia Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive null --- T315I ---